Arbutus Biopharma Corporation Stock News

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 10% during intraday trading today. This is why it happened.

Screening identifies several unique compound series that inhibit the SARS-CoV-2 nsp5 main protease, a validated target for the treatment of COVID-19 and potential future coronavirus outbreaks

Arbutus Biopharma Corporation (NASDAQ: ABUS) has identified several molecules that inhibit the SARS-CoV-2 nsp5 main protease (Mpro), a validated target for treating COVID-19 and potential future co

In the last trading session, 18.04 million Arbutus Biopharma Corporation (NASDAQ:ABUS) shares changed hands as the company’s beta touched 2.60. With the company’s per share price at $4.15 changed hands at -$0.16 or -3.71% during last session, the market valuation stood at $582.99M. ABUS’s last price was a discount, traded about -56.63% off its 52-week … Arbutus Biopharma Corporation (NASDAQ: ABUS) Is Expected To Soar To Higher Prices In The Months To Come. Read More »

Arbutus Biopharma (NASDAQ:ABUS) had its price target raised by Chardan Capital from $5.00 to $5.50 in a research note published on Thursday morning, The Fly reports. Chardan Capital currently has a buy rating on the biopharmaceutical companys stock. Other research analysts have also recently issued reports about the company. HC Wainwright cut their price target [] The post Arbutus Biopharma (NASDAQ:ABUS) Price Target Raised to $5.50 at Chardan Capital appeared first on ETF Daily News .

Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) have received a consensus rating of Buy from the six analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokers that have []

Arbutus Biopharma Co. (NASDAQ:ABUS) saw an uptick in trading volume on Wednesday . 814,409 shares were traded during mid-day trading, a decline of 61% from the previous sessions volume of 2,086,054 shares.The stock last traded at $4.40 and had previously closed at $3.20. A number of brokerages recently commented on ABUS. JMP Securities lifted their []

Arbutus Biopharma Co. (NASDAQ:ABUS) shares saw strong trading volume on Wednesday . 814,409 shares changed hands during trading, a decline of 61% from the previous sessions volume of 2,086,054 shares.The stock last traded at $4.40 and had previously closed at $3.20. A number of equities analysts have weighed in on the stock. HC Wainwright reduced []

The patents subject to the court's ruling cover a lipid formulation for nucleic acid delivery, which is essential for Moderna's COVID-19 vaccines.

The stock price of Arbutus Biopharma Corp (NASDAQ: ABUS) increased by over 50% during intraday trading today. This is why it happened.

Arbutus Biopharma Corporation (NASDAQ: ABUS) has announced preliminary data from its Phase 1a/1b trial of AB-836, an oral hepatitis B virus (HBV) capsid inhibitor that interacts with HBV core prote

Arbutus Biopharma Corp (NASDAQ: ABUS) is soaring Wednesday after The Patent Trial and Appeals Board turned down Moderna Inc's (NASDAQ: MRNA) appeal to invalidate two of Arbutus' patents on drug-del

Shares of small-cap biotech Arbutus Biopharma Corporation (NASDAQ: ABUS) are advancing strongly on above-average volume on Wednesday. What Happened: The Patent Trial and Appeals Board has turned down